

What's Up with U.S. Merger Remedies? A Podcast Episode Featuring Jeny Maier

A photograph of a modern building with a curved glass facade, showing multiple floors and windows, set against a light blue sky.

LESS THAN 1 MIN READ

February 26, 2024, 3:14 PM

By: Axinn Insights

The US antitrust agencies' approach to merger remedies has undergone a significant change under the Biden administration. Remedies are increasingly disfavored.

Axinn's Managing Partner [Jeny Maier](#) joins Dan Ducore, former Assistant Director of the Federal Trade Commission's Bureau of Competition Compliance Division, and co-host Barry Nigro on *Our Curious Amalgam* to discuss the growing skepticism towards merger remedies by the US antitrust authorities.

Listen to this episode to learn more about whether merger remedies remain a viable option in the US and, if so, how parties should approach them given the government's current hostility toward remedies.



Related Services

Antitrust

To subscribe to our publications, [click here](#).

TAGS

regulatory

News & Insights

- ACI Forum on Pharma & Biotech Patent Litigation USA 2025
SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY
- CCWC 21st Annual Career Strategies Conference
SPEAKING ENGAGEMENT
- Fordham 52nd Annual Conference on International Antitrust Law and Policy
SPEAKING ENGAGEMENT ANTITRUST
- Kisaco Research Trade Secret Legal Protection Conference 2025
SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY
- SCCE 23rd Annual Compliance & Ethics Institute
SPEAKING ENGAGEMENT ANTITRUST

- 29th Annual IBA Competition Conference

SPONSORSHIP ANTITRUST

- Key Appellate Decisions Shaping Antitrust Strategy

WEBINAR ANTITRUST

- New Frontiers of Antitrust – 16th Annual International Conference of Concurrences Review

SPEAKING ENGAGEMENT ANTITRUST

- MCCA Pathways Conference

SPONSORSHIP ANTITRUST

- HNBA/VIA Annual Convention 2025

SPONSORSHIP ANTITRUST

© 2025 Axinn, Veltrop & Harkrider LLP. All Rights Reserved